AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17251666 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 7
Study 17258088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) in patients with unstable angina (UA)
Number of subjects: 607
Study 17258088 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) in patients with stable angina (SA)
Number of subjects: 607
Study 17263626 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon/ribavirin therapy
Number of subjects: 91
Study 17276184 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher log-CRP concentration in men
Number of subjects: 1164
Study 17278106 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLL cells from a subset of patients
Number of subjects: 0
Study 17296644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction during exacerbation
Number of subjects: 44
Study 17296644 — intervention group
Group type: COMPARATOR
Intervention: Sputum induction during stable phase
Number of subjects: 44
Study 17296825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1748
Study 17296825 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1748
Study 17296825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (in patients with diabetes)
Number of subjects: 1748
Study 17296825 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (in patients with diabetes)
Number of subjects: 1748
Study 17296825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1748
Study 17310025 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 27937
Study 17310025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 27937
Study 17310025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 27937
Study 17310025 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol to HDL-C ratio
Number of subjects: 27937
Study 17310025 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HDL-C
Number of subjects: 27937
Study 17325261 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 0
Study 17325261 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 17329707 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia correction intervention
Number of subjects: 0
Study 17332146 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine
Number of subjects: 24968
Study 17332146 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR genotype (TT vs CC)
Number of subjects: 24968
Study 17332146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of folate/B-vitamins
Number of subjects: 24968
Study 17337677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline inhalation
Number of subjects: 0
Study 17344250 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Living Allowance (DLA) application
Number of subjects: 156
Study 17344250 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Living Allowance (DLA) monetary award
Number of subjects: 156
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine < 0.9 mg/dl
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine 0.9-1.2 mg/dl
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine 1.2-1.6 mg/dl
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine 1.6-2.8 mg/dl
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine >= 2.8 mg/dl
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine (per mg/dl) in LIFE study
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine (per mg/dl) in RENAAL study
Number of subjects: 2708
Study 17351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine (per mg/dl) in combined studies
Number of subjects: 2708
Study 17356709 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6-dimethylxanthenone-4-acetic acid (DMXAA) 30 mg/kg, i.p.
Number of subjects: 0
Study 17356709 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 17360989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem-cell autograft followed by allograft from an HLA-identical sibling
Number of subjects: 162
Study 17360989 — intervention group
Group type: COMPARATOR
Intervention: Tandem autografts (double-autologous-transplant group)
Number of subjects: 162
Study 17360989 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft-allograft group
Number of subjects: 162
Study 17360989 — intervention group
Group type: EXPERIMENTAL
Intervention: Allografting
Number of subjects: 162
Study 17360989 — intervention group
Group type: COMPARATOR
Intervention: Double-autologous-transplant group
Number of subjects: 162
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite three-marker test (CRP, PCT, Neutrophils)
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite six-marker test (CRP, PCT, Neutrophils, suPAR, sTREM-1, MIF)
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble triggering receptor expressed on myeloid cells (sTREM)-1
Number of subjects: 151
Study 17362525 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble urokinase-type plasminogen activator (suPAR)
Number of subjects: 151
Study 17372153 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 17377160 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CNS involvement
Number of subjects: 142
Study 17377160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary failure after CNS involvement
Number of subjects: 142
Study 17377160 — intervention group
Group type: COMPARATOR
Intervention: CNS involvement alone
Number of subjects: 142
Study 17379851 — intervention group
Group type: EXPERIMENTAL
Intervention: One deep inspiration
Number of subjects: 37
Study 17379851 — intervention group
Group type: EXPERIMENTAL
Intervention: Five deep inspirations
Number of subjects: 37
Study 17379851 — intervention group
Group type: EXPERIMENTAL
Intervention: Five deep inspirations before methacholine inhalation
Number of subjects: 37
Study 17392300 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 969
Study 17392561 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17395103 — intervention group
Group type: EXPERIMENTAL
Intervention: (124)I-cG250 PET
Number of subjects: 26
Study 17395103 — intervention group
Group type: COMPARATOR
Intervention: Inactive antibody
Number of subjects: 26
Study 17418291 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 216
Study 17425446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide therapy (120 microg)
Number of subjects: 166
Study 17426205 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 24
Study 17426205 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FMT PET
Number of subjects: 24
Study 17426205 — intervention group
Group type: COMPARATOR
Intervention: Control group (lung cancer patients) (18)F-FDG PET
Number of subjects: 24
Study 17426205 — intervention group
Group type: COMPARATOR
Intervention: Control group (lung cancer patients) (18)F-FMT PET
Number of subjects: 24
Study 17426205 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FMT PET in combination with (18)F-FDG PET
Number of subjects: 24
Study 17426276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST)
Number of subjects: 15
Study 17426276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunosuppression followed by AHST
Number of subjects: 15
Study 17431579 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variation in the PPARD gene
Number of subjects: 7495
Study 17436219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (highly active antiretroviral therapy)
Number of subjects: 22
Study 17448368 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté stent
Number of subjects: 0
Study 17448368 — intervention group
Group type: COMPARATOR
Intervention: TAXUS Express stent
Number of subjects: 0
Study 17448416 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-1 (full set of heart failure discharge instructions and education)
Number of subjects: 33681
Study 17448416 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Improvement (PI) tools
Number of subjects: 33681
Study 17450048 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct services for attrition prevention (ASAP)
Number of subjects: 439
Study 17460469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based HAART
Number of subjects: 64
Study 17462825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with painful myocardial infarction (MI)
Number of subjects: 92
Study 17462825 — intervention group
Group type: COMPARATOR
Intervention: Patients with painless myocardial infarction (MI)
Number of subjects: 92
Study 17475941 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat reduction diet
Number of subjects: 0
Study 17475941 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate reduction diet
Number of subjects: 0
Study 17488673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and dexamethasone
Number of subjects: 12
Study 17498579 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP quartile Q1 (<430 pg/ml)
Number of subjects: 48629
Study 17498579 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP quartile Q2 (430 to 839 pg/ml)
Number of subjects: 48629
Study 17498579 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP quartile Q3 (840 to 1,729 pg/ml)
Number of subjects: 48629
Study 17498579 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP quartile Q4 (>=1,730 pg/ml)
Number of subjects: 48629
Study 17502467 — intervention group
Group type: COMPARATOR
Intervention: Testosterone gel (10 g daily, containing 100 mg of testosterone)
Number of subjects: 10
Study 17503986 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 6 weeks, increased to 120 mg/day for the remainder of the 12-week trial as tolerated
Number of subjects: 24
Study 17504901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin measurement (hourly between 2300 and 0300 h)
Number of subjects: 72
Study 17504901 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h LH measurement
Number of subjects: 72
Study 17507719 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular targeted photodynamic therapy (VTP) with palladium-bacteriopheophorbide
Number of subjects: 25
Study 17512363 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP tSNP allele +1086A
Number of subjects: 4811
Study 17512363 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP tSNP -631AA
Number of subjects: 4811
Study 17512363 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP tSNP +2389GA
Number of subjects: 4811
Study 17512363 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis for LD group B
Number of subjects: 4811
Study 17512363 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis for LD group A
Number of subjects: 4811
Study 17512363 — intervention group
Group type: COMPARATOR
Intervention: TaqIB variant
Number of subjects: 4811
Study 17512363 — intervention group
Group type: COMPARATOR
Intervention: tSNP or haplotype associations with myocardial infarction (MI)
Number of subjects: 4811
Study 17515522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bexarotene and extracorporeal photopheresis
Number of subjects: 0
Study 17519207 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous platelet gel (APG)
Number of subjects: 8
Study 17519207 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (antibiotic ointment and/or semiocclusive dressing)
Number of subjects: 8
Study 17519207 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous platelet gel (APG) with platelet count > 6 times baseline
Number of subjects: 8
Study 17519207 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro testing of supplemental APG
Number of subjects: 8
Study 17530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-minute walk test
Number of subjects: 258
Study 17530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated chair rise test
Number of subjects: 258
Study 17530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (Paffenbarger Physical Activity and Exercise Index)
Number of subjects: 258
Study 17530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 258
Study 17530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term asthma control
Number of subjects: 258
Study 17530534 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between PAEI and performance-based tests
Number of subjects: 258
Study 17536019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (a phosphodiesterase-5 inhibitor)
Number of subjects: 0
Study 17541048 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation pharmacotherapy (bupropion, nortriptyline, or lithium)
Number of subjects: 195
Study 17541048 — intervention group
Group type: COMPARATOR
Intervention: No augmentation (control group)
Number of subjects: 195
Study 17541653 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 60,000 U SC QW during initial dosing phase (IDP)
Number of subjects: 115
Study 17541653 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 80,000 U SC Q3W during extended dosing phase (EDP)
Number of subjects: 115
Study 17541653 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 60,000 U SC QW during IDP
Number of subjects: 115
Study 17541653 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 80,000 U SC Q3W during EDP
Number of subjects: 115
Study 17543307 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS/EUS-FNA
Number of subjects: 17
Study 17543307 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 17
Study 17543307 — intervention group
Group type: COMPARATOR
Intervention: US
Number of subjects: 17
Study 17543307 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 17
Study 17543307 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 17
Study 17543307 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 17
Study 17544766 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine (n=9087)
Number of subjects: 20583
Study 17544766 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 vaccine component (n=1204)
Number of subjects: 20583
Study 17544766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10,292)
Number of subjects: 20583
Study 17544766 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPV vaccination (including all types)
Number of subjects: 20583
Study 17545184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tests for HIV-1
Number of subjects: 1517
Study 17545184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tests for HIV-1 (after excluding weak positive bands)
Number of subjects: 1517
Study 17557758 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg)
Number of subjects: 201
Study 17557758 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg)
Number of subjects: 201
Study 17557758 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Alendronate vs Alfacalcidol
Number of subjects: 201
Study 17557758 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 201
Study 17557758 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 201
Study 17558345 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous endotoxin immunoadsorption (IA), IL-6 IA, and C5a IA on 5 consecutive days for 7.5 h each
Number of subjects: 33
Study 17559726 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60-120 mg/day for 10 weeks or 60/120 mg/day for 9 weeks)
Number of subjects: 1163
Study 17559726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1163
Study 17560635 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node mapping with Tc-99 radiocolloid and blue dye
Number of subjects: 20
Study 17560635 — intervention group
Group type: COMPARATOR
Intervention: Blue dye alone
Number of subjects: 20
Study 17562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (20 mg/m2) + cyclophosphamide (200 mg/m2)
Number of subjects: 18
Study 17562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (10 mg/m2) + cyclophosphamide (200 mg/m2)
Number of subjects: 18
Study 17562873 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (200 mg/m2) alone
Number of subjects: 18
Study 17562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine + cyclophosphamide
Number of subjects: 18
Study 17563345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon
Number of subjects: 0
Study 17563345 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17563348 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual 4-day insulin infusions and daily insulin injections
Number of subjects: 298
Study 17563348 — intervention group
Group type: COMPARATOR
Intervention: Control group (closely monitored subjects)
Number of subjects: 298
Study 17563856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg once daily and docetaxel 75 mg/m(2) every 3 weeks
Number of subjects: 33
Study 17563856 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (as a comparison)
Number of subjects: 33
Study 17573503 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with COPD
Number of subjects: 396
Study 17573503 — intervention group
Group type: COMPARATOR
Intervention: Women with COPD
Number of subjects: 396
Study 17573882 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod treatment for AIN
Number of subjects: 21
Study 17577020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat 400 mg daily until disease progression or intolerable toxicity
Number of subjects: 74
Study 17577020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat 400 mg daily
Number of subjects: 74
Study 17579184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy/Flu/DLI
Number of subjects: 15
Study 17579184 — intervention group
Group type: COMPARATOR
Intervention: DLI without chemotherapy
Number of subjects: 15
Study 17579195 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone deficiency (GHD)
Number of subjects: 12
Study 17585106 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP >= 10 cm H(2)O and Fi(O(2)) >= 0.5 at Day 1
Number of subjects: 170
Study 17586030 — intervention group
Group type: EXPERIMENTAL
Intervention: HspE7 (500 microg, 3 monthly subcutaneous vaccinations)
Number of subjects: 58
Study 17586305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose AAV-GAD gene therapy
Number of subjects: 12
Study 17586305 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose AAV-GAD gene therapy
Number of subjects: 12
Study 17586305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AAV-GAD gene therapy
Number of subjects: 12
Study 17586305 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV-GAD gene therapy
Number of subjects: 12
Study 17586747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with rosiglitazone and exercise
Number of subjects: 0
Study 17586747 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17591525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU once weekly for 12 weeks and once monthly thereafter for a total of 6 months
Number of subjects: 66
Study 17591525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol administration
Number of subjects: 66
Study 17592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloset
Number of subjects: 3095
Study 17592632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3095
Study 17592924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low endogenous androgen production (measured as serum androgen levels)
Number of subjects: 43
Study 17592924 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone levels
Number of subjects: 43
Study 17592924 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone
Number of subjects: 43
Study 17596485 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17596541 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacitidine (5-AZA) at 75 mg/m² subcutaneously daily for 7 days, valproic acid (VPA) orally daily for 7 days (dose-escalated, maximum tolerated dose 50 mg/kg), all-trans retinoic acid (ATRA) at 45 mg/m² orally daily for 5 days starting on day 3.
Number of subjects: 53
Study 17596541 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 53
Study 17596541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-AZA, VPA, and ATRA
Number of subjects: 53
Study 17597266 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ-50300 smallpox vaccine
Number of subjects: 18
Study 17601897 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 192
Study 17601897 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 192